Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Matrix extracellular phosphoglycoprotein

Introduction

Matrix, extracellular phosphoglycoprotein with ASARM motif (bone), also known as MEPE, is a human gene.[1]

Phosphatonins have a role in phosphate homeostasis and the relationship between phosphate handling by the kidney and gastrointestinal tract. Matrix extracellular phosphoglycoprotein (MEPE), one of several candidate phosphatonins, promotes phosphaturia.[2] Short-term infusion of MEPE inhibits phosphate absorption in the jejunum but not the duodenum.[2] The phosphaturic action of MEPE may correlate with a significant reduction in renal sodium-phosphate co-transporter NaPi-IIa in the proximal convoluted tubules of the outer renal cortex.[2] This short-term inhibitory effect of MEPE on renal and intestinal phosphate handling occurs without changes in the circulating levels of parathyroid hormone (PTH), 1,25-dihydroxyvitamin D(3), or fibroblast growth factor 23 (FGF23).[2] MEPE may be involved in phosphate homeostasis, acting in both the kidney and the gastrointestinal tract.[2]

References

References

  1. ↑ “Entrez Gene: MEPE matrix, extracellular phosphoglycoprotein with ASARM motif (bone)”.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Marks J, Churchill LJ, Debnam ES, Unwin RJ (2008). “Matrix extracellular phosphoglycoprotein inhibits phosphate transport”. J Am Soc Nephrol. 19 (12): 2313–20. PMID 19005008. Unknown parameter |month= ignored (help)
Further reading

Further reading

  • Quarles LD (2003). “FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization”. Am. J. Physiol. Endocrinol. Metab. 285 (1): E1–9. doi:10.1152/ajpendo.00016.2003. PMID 12791601.
  • Ogbureke KU, Fisher LW (2005). “Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs)”. Kidney Int. 68 (1): 155–66. doi:10.1111/j.1523-1755.2005.00389.x. PMID 15954904.
  • Ogbureke KU, Fisher LW (2004). “Expression of SIBLINGs and their partner MMPs in salivary glands”. J. Dent. Res. 83 (9): 664–70. doi:10.1177/154405910408300902. PMID 15329369.
  • Jain A, Fedarko NS, Collins MT; et al. (2004). “Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density”. J. Clin. Endocrinol. Metab. 89 (8): 4158–61. doi:10.1210/jc.2003-032031. PMID 15292364.
  • Nampei A, Hashimoto J, Hayashida K; et al. (2005). “Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone”. J. Bone Miner. Metab. 22 (3): 176–84. doi:10.1007/s00774-003-0468-9. PMID 15108058.
  • MacDougall M, Simmons D, Gu TT, Dong J (2003). “MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21”. Connect. Tissue Res. 43 (2–3): 320–30. doi:10.1080/713713461. PMID 12489176.
  • Argiro L, Desbarats M, Glorieux FH, Ecarot B (2001). “Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone”. Genomics. 74 (3): 342–51. doi:10.1006/geno.2001.6553. PMID 11414762.
  • Rowe PS, de Zoysa PA, Dong R; et al. (2000). “MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia”. Genomics. 67 (1): 54–68. doi:10.1006/geno.2000.6235. PMID 10945470.